The field of hypertension is entering an exciting new era in which new conc
epts in basic and clinical science are being rapidly translated into new re
commendations for clinical practice. It is now readily apparent that an age
-related increase in stiffness of the walls of the large arteries causes th
e predominant hemodynamic characteristic of hypertension in later life: inc
reased systolic blood pressure. Systolic hypertension is now recognized to
have greater prognostic significance than diastolic hypertension, and it is
also known that the effective treatment of systolic hypertension confers a
proportional benefit in risk reduction. A rapidly advancing knowledge of v
ascular biology has revealed that the renin-angiotensin system plays a cent
ral role in the pathogenesis of vascular hypertrophy and arterial stiffness
. Angiotensin-converting enzyme inhibitors have been shown to reduce arteri
al stiffness to a greater degree than diuretics or beta-blockers. The pharm
acologic interruption of the renin-angiotensin system may therefore confer
previously unrecognized benefits on age-related vascular damage, providing
special benefits in systolic hypertension. Blood Press Monit 5 (suppl 2):S7
-S11 (C) 2000 Lippincott Williams & Wilkins.